The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Dec 2021
Historique:
received: 22 10 2021
revised: 18 12 2021
accepted: 19 12 2021
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 3 2 2022
Statut: epublish

Résumé

The main problem precluding successful therapy with conventional taxanes is de novo or acquired resistance to taxanes. Therefore, novel experimental taxane derivatives (Stony Brook taxanes; SB-Ts) are synthesized and tested as potential drugs against resistant solid tumors. Recently, we reported alterations in

Identifiants

pubmed: 35008510
pii: ijms23010073
doi: 10.3390/ijms23010073
pmc: PMC8744980
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Biomarkers, Tumor 0
LIM Domain Proteins 0
Multidrug Resistance-Associated Proteins 0
TRIP6 protein, human 0
Taxoids 0
Transcription Factors 0
multidrug resistance-associated protein 3 1YV0492L5Z
CPS1 protein, human EC 6.3.4.16
Carbamoyl-Phosphate Synthase (Ammonia) EC 6.3.4.16
Paclitaxel P88XT4IS4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Czech Science Foundation
ID : 19-03063S
Organisme : Czech Health Research Council
ID : NU20-09-00174
Organisme : Charles University
ID : PROGRES Q28
Organisme : Czech Ministry of Education, Youth and Sports
ID : INTER-COST, LTC19020
Organisme : NIH HHS
ID : R01 CA103314
Pays : United States

Références

Nature. 2017 Jun 1;546(7656):168-172
pubmed: 28538732
Biol Cell. 2011 Dec 1;103(12):573-91
pubmed: 22054418
Semin Oncol Nurs. 2019 Apr;35(2):151-156
pubmed: 30867104
Gynecol Oncol. 2010 May;117(2):198-201
pubmed: 19922990
Anticancer Res. 2005 Nov-Dec;25(6B):4215-24
pubmed: 16309219
J Exp Clin Cancer Res. 2012 Feb 13;31:14
pubmed: 22330607
J Cancer. 2017 Oct 9;8(17):3598-3606
pubmed: 29151946
PLoS One. 2016 May 12;11(5):e0155013
pubmed: 27171227
Cancer Med. 2019 Feb;8(2):606-616
pubmed: 30672151
J Biol Chem. 2009 May 22;284(21):14558-71
pubmed: 19293149
Int J Mol Sci. 2019 Jun 19;20(12):
pubmed: 31248089
Oncol Rep. 2016 Apr;35(4):2159-70
pubmed: 26820484
Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):273-93
pubmed: 25380746
J Biol Chem. 2004 Mar 12;279(11):10459-68
pubmed: 14688263
J Biol Chem. 2007 Dec 28;282(52):37759-69
pubmed: 17965021
Curr Opin Plant Biol. 2004 Jun;7(3):254-61
pubmed: 15134745
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Nucleic Acids Res. 2002 May 1;30(9):e36
pubmed: 11972351
Cold Spring Harb Perspect Biol. 2013 Sep 01;5(9):
pubmed: 24003207
Invest New Drugs. 2011 Jun;29(3):411-23
pubmed: 20013348
Toxicol Appl Pharmacol. 2016 Nov 1;310:215-228
pubmed: 27664577
Cancer Res. 2008 Jul 1;68(13):5380-9
pubmed: 18593940
Int J Mol Sci. 2016 Dec 15;17(12):
pubmed: 27983698
Turk J Gastroenterol. 2019 Apr;30(4):326-330
pubmed: 30945643
Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):1035-48
pubmed: 22855252
Int J Oncol. 2014 Aug;45(2):822-30
pubmed: 24898082
Am J Cancer Res. 2021 Sep 15;11(9):4127-4140
pubmed: 34659880
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Cancer Chemother Pharmacol. 2013 Jan;71(1):153-63
pubmed: 23053273
Cancers (Basel). 2020 Jun 17;12(6):
pubmed: 32560564
Drug Resist Updat. 2021 Mar;55:100754
pubmed: 33691261
Tumour Biol. 2015 Jun;36(6):4327-38
pubmed: 25596703
Mol Cancer Res. 2019 Jun;17(6):1351-1364
pubmed: 30808730
Adv Protein Chem Struct Biol. 2017;108:163-198
pubmed: 28427560
J Exp Clin Cancer Res. 2019 Aug 5;38(1):312
pubmed: 31378204
Lancet. 2021 Jan 23;397(10271):281-292
pubmed: 33485453
Cancers (Basel). 2021 Feb 11;13(4):
pubmed: 33670206
Mutagenesis. 2019 Dec 19;34(5-6):403-411
pubmed: 31375828
Toxicol Appl Pharmacol. 2018 May 15;347:79-91
pubmed: 29625142
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Adv Biol Regul. 2019 Aug;73:100634
pubmed: 31053501
CA Cancer J Clin. 2019 Jul;69(4):280-304
pubmed: 31099893
Sci Rep. 2021 Apr 1;11(1):7400
pubmed: 33795761
Exp Cell Res. 2015 Apr 10;333(1):1-10
pubmed: 25557873
Mitochondrion. 2017 Mar;33:2-14
pubmed: 27444749
Oncology (Williston Park). 2018 Aug 15;32(8):418-20, 422-4
pubmed: 30153322
Gynecol Oncol. 2017 Feb;144(2):396-404
pubmed: 27919574
J Cell Physiol. 2018 Jun;233(6):5034-5043
pubmed: 29219179
J Cell Sci. 2012 Feb 15;125(Pt 4):807-15
pubmed: 22448037
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813239
Cancers (Basel). 2021 Apr 06;13(7):
pubmed: 33917483
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Clin Oncol. 1991 Mar;9(3):389-93
pubmed: 1999708
Stem Cells. 2005 Oct;23(9):1417-22
pubmed: 16051985
Sci Rep. 2013 Nov 01;3:3120
pubmed: 24176985
J Natl Cancer Inst. 2017 Mar 1;109(3):1-9
pubmed: 28376202
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
Zhonghua Yi Xue Za Zhi. 2014 Jul 15;94(27):2148-51
pubmed: 25327865
J Mol Cell Biol. 2016 Jun;8(3):282-5
pubmed: 27025967
Tumour Biol. 2016 Jan;37(1):1369-78
pubmed: 26298725
Naunyn Schmiedebergs Arch Pharmacol. 2005 Jul;372(1):95-105
pubmed: 16059735
J Nat Prod. 2009 Mar 27;72(3):554-65
pubmed: 19239240
Sci Rep. 2015 Nov 23;5:16950
pubmed: 26592762
Anticancer Res. 2009 Aug;29(8):2951-60
pubmed: 19661300
PLoS One. 2019 Feb 28;14(2):e0212097
pubmed: 30817750
Int J Oncol. 2017 Mar;50(3):893-902
pubmed: 28197640
Cancer Res. 2019 Jul 1;79(13):3332-3346
pubmed: 31018940
Tumour Biol. 2014 Nov;35(11):11097-105
pubmed: 25099619
Bioorg Chem. 2020 Jan;95:103523
pubmed: 31911305

Auteurs

Karolina Seborova (K)

Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic.

Alzbeta Kloudova-Spalenkova (A)

Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic.
Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic.

Kamila Koucka (K)

Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic.

Petr Holy (P)

Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic.
Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic.

Marie Ehrlichova (M)

Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic.

Changwei Wang (C)

Institute of Chemical Biology & Drug Discovery, Stony Brook University-State University of New York, Stony Brook, NY 11794, USA.

Iwao Ojima (I)

Institute of Chemical Biology & Drug Discovery, Stony Brook University-State University of New York, Stony Brook, NY 11794, USA.

Iveta Voleska (I)

Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic.

Petr Daniel (P)

Division of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic.

Kamila Balusikova (K)

Division of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic.

Michael Jelinek (M)

Division of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic.

Jan Kovar (J)

Division of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic.

Lukas Rob (L)

Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic.

Martin Hruda (M)

Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic.

Marcela Mrhalova (M)

Department of Pathology and Molecular Medicine, Second Faculty of Medicine and Motol University Hospital, 150 06 Prague, Czech Republic.

Pavel Soucek (P)

Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic.

Radka Vaclavikova (R)

Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH